Obesity Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, An

Obesity Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Betagenon AB, BioRestorative, Boehringer Ingelheim, Braasch Biotech, Bristol-Myers Squibb, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina, CinFina Pharma, Clayton Biotech, Click Therapeutics, CohBar, Corbus Pharma, CSPC Baike (Shandong) Biopharmaceutical, D&D Pharmatech Co Ltd, Daewoong Pharmaceutical, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Paige Biopharmaceutical (Suzhou) Co., Ltd. , Pfizer, Preveceutical Medical Inc, Pylum Biosciences, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, RosVivo Therapeutics, Saniona, SciSparc Ltd., Sciwind Biosciences, SCOHIA PHARMA, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma

Obesity Pipeline constitutes 80+ key companies continuously working towards developing 100+ Obesity treatment therapies, analyzes DelveInsight.

Obesity Overview:

Obesity is characterized by the excessive accumulation of fat or adipose tissue in the body, leading to health complications such as diabetes, cardiovascular disease, hypertension, and hyperlipidemia. Over the past five decades, it has become a growing public health crisis. As a complex condition with multiple contributing factors, obesity ranks as the second leading cause of preventable death after smoking. Losing just 5% to 10% of body weight can significantly enhance overall health, quality of life, and reduce economic strain on individuals and healthcare systems. Obesity results from an imbalance between calorie intake and energy expenditure, leading to excessive weight gain. It is influenced by a combination of genetic, cultural, and societal factors. Studies indicate a strong genetic predisposition to obesity, with several genes linked to weight gain and adiposity. Other contributing factors include reduced physical activity, sleep deprivation, endocrine disorders, certain medications, easy access to high-calorie foods, and decreased energy metabolism.

Request for a detailed insights report on Obesity pipeline insights @ https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Obesity Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Obesity Therapeutics Market.

Key Takeaways from the Obesity Pipeline Report

DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment.
In June 2024, NeuroBo Pharmaceuticals began dosing the first patient in Part 2 of its global Phase I clinical trial for DA-1726, a potential obesity treatment, in the United States.
In May 2024, Metaphore Biotechnologies partnered with Flagship Pioneering to collaborate with Novo Nordisk on developing up to two next-generation obesity therapeutics. This initiative is part of a broader strategic partnership aimed at advancing novel treatments for cardiometabolic and rare diseases.
In May 2024, Click Therapeutics, Inc. announced plans to accelerate its obesity and cardiometabolic disease programs by acquiring Better Therapeutics, Inc.'s assets, including AspyreRx (BT-001) for type 2 diabetes and BT-004 for metabolic dysfunction-associated steatohepatitis (MASH).
In March 2024, iBio, Inc. entered into a collaboration with AstralBio, Inc. to discover, engineer, and develop novel antibody-based treatments for obesity and other cardiometabolic disorders.
In February 2024, BioAge Labs, a biotech company working with Eli Lilly on obesity therapies, secured $170 million in its latest funding round.
In January 2024, Adipo Therapeutics successfully completed a $1.9 million bridge funding round, bringing its total seed funding to $4 million to advance its lead candidate, ADPO-002, which aims to treat obesity by enhancing energy expenditure.
Key Obesity companies such as 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Betagenon AB, BioRestorative, Boehringer Ingelheim, Braasch Biotech, Bristol-Myers Squibb, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina, CinFina Pharma, Clayton Biotech, Click Therapeutics, CohBar, Corbus Pharma, CSPC Baike (Shandong) Biopharmaceutical, D&D Pharmatech Co Ltd, Daewoong Pharmaceutical, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Paige Biopharmaceutical (Suzhou) Co., Ltd. , Pfizer, Preveceutical Medical Inc, Pylum Biosciences, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, RosVivo Therapeutics, Saniona, SciSparc Ltd., Sciwind Biosciences, SCOHIA PHARMA, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others are evaluating new drugs for Obesity to improve the treatment landscape.
Promising Obesity pipeline therapies in various stages of development include Semaglutide Oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, GSBR-1290, K757, BI 1356225, Bardoxolone methyl, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, Small Molecule, YH34160, NM-136, Rsearch programme: Obesity, DA-1726, Era-379, Research programme: NaCT inhibitors, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, Obesity Research project, CLS-1, O304 AMPK Activators, Obesity Research project, Novel vaccine Obesity Research project, CV-08, HI P. Goldsteinii, CRB-913, Tespria, Next Generation Candidates, AM 6545, LP-003, KT A522, JD5037, Research program: Amylin targeting, Obesity research program, Dual Gene Therapy program, RP 1208, SiPore® platform based therapy, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, Recombinant growth differentiation factor 11, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others.

Obesity Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Obesity Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Obesity market.

Download our free sample page report on Obesity pipeline insights @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Obesity Emerging Drugs

Survodutide: Zealand Pharma
Ecnoglutide: Sciwind Biosciences
CT-868: Carmot Therapeutics
DD01: D&D Pharmatech

Obesity Companies

Obesity companies working in the market are 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Betagenon AB, BioRestorative, Boehringer Ingelheim, Braasch Biotech, Bristol-Myers Squibb, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina, CinFina Pharma, Clayton Biotech, Click Therapeutics, CohBar, Corbus Pharma, CSPC Baike (Shandong) Biopharmaceutical, D&D Pharmatech Co Ltd, Daewoong Pharmaceutical, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Paige Biopharmaceutical (Suzhou) Co., Ltd. , Pfizer, Preveceutical Medical Inc, Pylum Biosciences, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, RosVivo Therapeutics, Saniona, SciSparc Ltd., Sciwind Biosciences, SCOHIA PHARMA, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others.

Approximately 80+ companies are actively developing therapies for obesity. Among them, Zealand Pharma has its obesity drug candidates in the most advanced stage of development, currently in Phase III clinical trials.

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Obesity Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Obesity Therapies and Key Companies: Obesity Clinical Trials and advancements @ https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Obesity Pipeline Therapeutic Assessment
• Obesity Assessment by Product Type
• Obesity By Stage
• Obesity Assessment by Route of Administration
• Obesity Assessment by Molecule Type

Download Obesity Sample report to know in detail about the Obesity treatment market @ Obesity Therapeutic Assessment @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Obesity Current Treatment Patterns
4. Obesity - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Obesity Late-Stage Products (Phase-III)
7. Obesity Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Obesity Discontinued Products
13. Obesity Product Profiles
14. Obesity Key Companies
15. Obesity Key Products
16. Dormant and Discontinued Products
17. Obesity Unmet Needs
18. Obesity Future Perspectives
19. Obesity Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Obesity Pipeline Reports Offerings: https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.